Information Provided By:
Fly News Breaks for September 25, 2019
NBIX
Sep 25, 2019 | 10:59 EDT
RBC Capital analyst Brian Abrahams noted that a posting to the ClinicalTrials.gov site revealed that Neurocrine Biosciences is studying the use of Ingrezza in the treatment of Huntington's Chorea. He thinks that Ingrezza's strong position in the tardive dyskinesia market could be a boon for the drug in a new indication and predicts that eventual approval in Huntington's could potentially add as much as an added 20% to out-year revenue estimates for the drug. Abrahams keeps an Outperform rating on Neurocrine shares.
News For NBIX From the Last 2 Days
NBIX
NBIX
NBIX
NBIX
NBIX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.